Publications by authors named "L Martinet"

Article Synopsis
  • Multiple myeloma (MM) is still an incurable cancer despite available therapies, with T-cell bispecific antibodies (TCBs) targeting BCMA and GPRC5D showing promise but facing issues like resistance and relapse due to antigen loss.
  • Forimtamig is a novel GPRC5D-targeting TCB that works more effectively than traditional formats by forming stable immunological connections, leading to better tumor cell destruction and T cell activation in preclinical studies.
  • Current research is exploring forimtamig in clinical trials for relapsed and refractory MM patients, both alone and alongside traditional care and new therapies, to enhance treatment outcomes and prevent relapses.
View Article and Find Full Text PDF

Background And Objectives: The rs763361 nonsynonymous variant in the gene, which results in a glycine-to-serine substitution at position 307 of the CD226 protein, has been implicated as a risk factor of various immune-mediated diseases, including multiple sclerosis (MS). Compelling evidence suggests that this allele may play a significant role in predisposing individuals to MS by decreasing the immune-regulatory capacity of Treg cells and increasing the proinflammatory potential of effector CD4 T cells. However, the impact of this CD226 gene variant on CD8 T-cell functions, a population that also plays a key role in MS, remains to be determined.

View Article and Find Full Text PDF

The promising results obtained with immunotherapeutic approaches for multiple myeloma (MM) call for a better stratification of patients based on immune components. The most pressing being cytotoxic lymphocytes such as natural killer (NK) cells that are mandatory for MM surveillance and therapy. Here, we performed a single-cell RNA sequencing analysis of NK cells from 10 patients with MM and 10 age/sex-matched healthy donors that revealed important transcriptomic changes in the NK cell landscape affecting both the bone marrow (BM) and peripheral blood compartment.

View Article and Find Full Text PDF

Multiple myeloma is characterized by a huge heterogeneity at the molecular level. The RAS/RAF pathway is the most frequently mutated, in ∼50% of the patients. However, these mutations are frequently subclonal, suggesting a secondary event.

View Article and Find Full Text PDF